News headlines about Cerus (NASDAQ:CERS) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cerus earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.4208626053459 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
CERS has been the topic of several research analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $5.00 target price on shares of Cerus in a research note on Tuesday, January 23rd. Zacks Investment Research downgraded Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Robert W. Baird reiterated a “buy” rating and set a $5.00 price target on shares of Cerus in a research report on Friday, December 1st. BTIG Research reiterated a “hold” rating on shares of Cerus in a research report on Thursday, January 25th. Finally, BidaskClub downgraded Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.83.
Cerus (CERS) traded up $0.13 during trading hours on Wednesday, hitting $4.13. The company had a trading volume of 910,086 shares, compared to its average volume of 1,940,000. Cerus has a 12-month low of $1.93 and a 12-month high of $5.43. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71. The firm has a market capitalization of $477.24, a PE ratio of -7.00 and a beta of 2.22.
ILLEGAL ACTIVITY WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cerus-cers-stock-price.html.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.